{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-030888","form_type":"8-K","ticker":"GILD","cik":"0000882095","company_name":"GILEAD SCIENCES, INC.","filed_at":"2022-03-07T23:59:59+00:00","discovered_at":"2026-05-14T18:04:10.143303+00:00","generated_at":"2026-06-27T01:22:32.554833+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Gilead's Trodelvy meets Phase 3 endpoint in HR+/HER2- metastatic breast cancer","bullets":["TROPiCS-02 met primary endpoint: statistically significant PFS improvement vs physician's choice chemo in 543 patients.","First interim OS analysis showed numerical improvement but not statistically significant; final OS readout expected in 2024.","Safety profile consistent with prior studies; no new safety concerns observed.","Gilead reaffirms 2022 guidance; oncology revenue goal of 1/3 by 2030 unchanged."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-030888","json":"https://secwatch.observer/filing/0001104659-22-030888.json","markdown":"https://secwatch.observer/filing/0001104659-22-030888.md","text":"https://secwatch.observer/filing/0001104659-22-030888.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882095/000110465922030888/0001104659-22-030888-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882095/000110465922030888/tm228518d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T01:22:32.554833+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}